Varonis Launches HackerOne Vulnerability Disclosure Program
New program harnesses the world’s top ethical hackers to enhance product security NEW YORK, Nov….
Month: November 2022
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX”…
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX”…
Parexel Announces Significant Recognition for Diversity and Workplace Culture in Asia/Pacific Region; Reaches Significant Company Milestone in Japan
Recent achievements showcase company’s leadership as CRO Partner and Employer of Choice in the Asia/Pacific region…
Parexel Announces Significant Recognition for Diversity and Workplace Culture in Asia/Pacific Region; Reaches Significant Company Milestone in Japan
Recent achievements showcase company’s leadership as CRO Partner and Employer of Choice in the Asia/Pacific region…
Mountain Valley MD Provides Business Update, Focus On Commercialization Phase
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
Mountain Valley MD Provides Business Update, Focus On Commercialization Phase
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics SAN DIEGO,…
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics SAN DIEGO,…
Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic…
Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic…
Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM”
ESTERO, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) — Mushrooms Inc. (OTC: MSRM) (the “Company”), formerly…
Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM”
ESTERO, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) — Mushrooms Inc. (OTC: MSRM) (the “Company”), formerly…
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical,…
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical,…
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409…
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409…
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour…
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour…
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD…